These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

734 related items for PubMed ID: 7542945

  • 21. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ, Gulati SC, Tong WP, Menendez-Botet C, Lyn P, Mazumdar M, Vlamis V, Lin S, Bosl GJ.
    Cancer Res; 1993 Aug 15; 53(16):3730-5. PubMed ID: 8393380
    [Abstract] [Full Text] [Related]

  • 22. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables.
    Vaena DA, Abonour R, Einhorn LH.
    J Clin Oncol; 2003 Nov 15; 21(22):4100-4. PubMed ID: 14615439
    [Abstract] [Full Text] [Related]

  • 23. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb 15; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 24. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
    Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L, Deluca J, Budnick A, Ishill N, Mazumdar M, Bosl GJ, Motzer RJ.
    J Clin Oncol; 2007 Jan 01; 25(1):85-90. PubMed ID: 17194908
    [Abstract] [Full Text] [Related]

  • 25. Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.
    Motzer RJ, Bajorin DF, Vlamis V, Weisen S, Bosl GJ.
    Semin Oncol; 1992 Dec 01; 19(6 Suppl 12):8-11. PubMed ID: 1336624
    [Abstract] [Full Text] [Related]

  • 26. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
    Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, Beyer J.
    J Clin Oncol; 2011 Jun 01; 29(16):2178-84. PubMed ID: 21444870
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP, Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
    J Clin Oncol; 2008 Jan 20; 26(3):421-7. PubMed ID: 18202419
    [Abstract] [Full Text] [Related]

  • 29. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec 20; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

  • 30. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S, Theodore C, Terrier-Lacombe MJ, Droz JP.
    J Urol; 1997 Mar 20; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Chemotherapy of disseminated germ cell tumors].
    Kimura G, Akimoto M.
    Gan To Kagaku Ryoho; 1998 Oct 20; 25(12):1873-90. PubMed ID: 9797810
    [Abstract] [Full Text] [Related]

  • 33. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
    De Giorgi U, Rosti G, Papiani G, Marangolo M.
    Haematologica; 2002 Jan 20; 87(1):95-104. PubMed ID: 11801470
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
    Sammler C, Beyer J, Bokemeyer C, Hartmann JT, Rick O.
    Eur J Cancer; 2008 Jan 20; 44(2):237-43. PubMed ID: 18055194
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
    Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R.
    N Engl J Med; 2007 Jul 26; 357(4):340-8. PubMed ID: 17652649
    [Abstract] [Full Text] [Related]

  • 38. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol.
    Kellie SJ, Boyce H, Dunkel IJ, Diez B, Rosenblum M, Brualdi L, Finlay JL.
    J Clin Oncol; 2004 Mar 01; 22(5):846-53. PubMed ID: 14990640
    [Abstract] [Full Text] [Related]

  • 39. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
    Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, Valero V, Booser DJ, Singletary SE, Strom EA, Gajewski JL, Champlin RE, Hortobagyi GN.
    Cancer; 2006 Jun 01; 106(11):2327-36. PubMed ID: 16639731
    [Abstract] [Full Text] [Related]

  • 40. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug 01; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.